EBS Emergent BioSolutions Inc

  1. Stocks
  2. Healthcare
  3. NYSE: EBS

Price (delayed)

$8.14

Market cap

$408.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.47

Enterprise value

$1.17B

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated ...

Highlights
The net income has plunged by 197% YoY
EBS's quick ratio has shrunk by 71% YoY and by 60% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.emergentbiosolutions.com
Peers: MRK SIGA XOMA CMRX

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
50.14M
Market cap
$408.14M
Enterprise value
$1.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.05
Earnings
Revenue
$1.12B
EBIT
-$184.4M
EBITDA
-$41.1M
Free cash flow
-$149.9M
Per share
EPS
-$4.47
Free cash flow per share
-$2.99
Book value per share
$27.72
Revenue per share
$22.37
TBVPS
$44.3
Balance sheet
Total assets
$3.17B
Total liabilities
$1.78B
Debt
$1.41B
Equity
$1.38B
Working capital
-$19.2M
Liquidity
Debt to equity
1.02
Current ratio
0.98
Quick ratio
0.65
Net debt/EBITDA
-18.57
Margins
EBITDA margin
-3.7%
Gross margin
38.1%
Net margin
-20%
Operating margin
-15.4%
Efficiency
Return on assets
-7.7%
Return on equity
-15.1%
Return on invested capital
-8.7%
Return on capital employed
-9.5%
Return on sales
-16.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
-0.37%
1 week
-15.65%
1 month
-41.77%
1 year
-80.86%
YTD
-31.08%
QTD
-31.08%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.12B
Gross profit
$427.2M
Operating income
-$172.7M
Net income
-$223.8M
Gross margin
38.1%
Net margin
-20%
The net income has plunged by 197% YoY
The company's operating margin has shrunk by 178% YoY
EBS's operating income has plunged by 149% YoY
EBS's gross profit has dropped by 59% year-on-year and by 48% since the previous quarter

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
N/A
P/B
0.29
P/S
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.05
The price to book (P/B) is 88% lower than the 5-year quarterly average of 2.4 and 68% lower than the last 4 quarters average of 0.9
EBS's equity is down by 15% year-on-year and by 4.6% since the previous quarter
The P/S is 86% below the 5-year quarterly average of 2.6 and 54% below the last 4 quarters average of 0.8
The company's revenue fell by 37% YoY and by 26% QoQ

Efficiency

How efficient is Emergent BioSolutions business performance
The company's return on assets has shrunk by 197% YoY
EBS's ROS has dropped by 185% year-on-year
EBS's ROIC has shrunk by 150% YoY

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 78% more than the total liabilities
Emergent BioSolutions's current ratio has plunged by 76% from the previous quarter and by 71% YoY
EBS's quick ratio has shrunk by 71% YoY and by 60% QoQ
The debt to equity has soared by 96% YoY and by 40% QoQ
Emergent BioSolutions's debt has surged by 67% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.